Cargando…
Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement
The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 3...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303957/ https://www.ncbi.nlm.nih.gov/pubmed/34300268 http://dx.doi.org/10.3390/jcm10143102 |
_version_ | 1783727216333422592 |
---|---|
author | Tamm, Alexander R. Geyer, Martin Kreidel, Felix Dausmann, Lea Jablonski, Caroline Hahad, Omar Schulz, Eberhard Münzel, Thomas Von Bardeleben, Ralph Stephan |
author_facet | Tamm, Alexander R. Geyer, Martin Kreidel, Felix Dausmann, Lea Jablonski, Caroline Hahad, Omar Schulz, Eberhard Münzel, Thomas Von Bardeleben, Ralph Stephan |
author_sort | Tamm, Alexander R. |
collection | PubMed |
description | The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 359 consecutive patients with severe aortic stenosis who underwent TAVR with S3 or ER from 2014–2016 (mean age 82 ± 7 years, 47% male, mean EuroSCORE II 8.0 ± 8%, mean follow-up 3.8 years). Device Success was equal (S3 93.0% vs. ER 92.4%, p = 0.812). We report a 30-day mortality of 2.8% in the S3 group, and 2.1% in the ER group (p = 0.674). There was no difference in stroke, conversion to open surgery, vascular and bleeding complications or myocardial infarction. While prosthesis mean gradients were higher with S3 (12.0 mmHg vs. 8.2 mmHg, p < 0.001), there was a trend to less paravalvular regurgitation (PVR moderate or severe: 1% vs. 3.6%, p = 0.088). All-cause mortality up to 5 years did not show a difference (mean survival S3 3.5 ± 0.24 years, ER 3.3 ± 0.29 years, p = 0.895). Independent predictors of long-term mortality were impaired LVEF, chronic kidney injury, peripheral artery disease, malignant tumor and periprocedural stroke. New generation TAVR valves offer an excellent implant and outcome success rate. Long-term survival was independent of prostheses choice and mainly attributed to comorbidities and complications. |
format | Online Article Text |
id | pubmed-8303957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83039572021-07-25 Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement Tamm, Alexander R. Geyer, Martin Kreidel, Felix Dausmann, Lea Jablonski, Caroline Hahad, Omar Schulz, Eberhard Münzel, Thomas Von Bardeleben, Ralph Stephan J Clin Med Article The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 359 consecutive patients with severe aortic stenosis who underwent TAVR with S3 or ER from 2014–2016 (mean age 82 ± 7 years, 47% male, mean EuroSCORE II 8.0 ± 8%, mean follow-up 3.8 years). Device Success was equal (S3 93.0% vs. ER 92.4%, p = 0.812). We report a 30-day mortality of 2.8% in the S3 group, and 2.1% in the ER group (p = 0.674). There was no difference in stroke, conversion to open surgery, vascular and bleeding complications or myocardial infarction. While prosthesis mean gradients were higher with S3 (12.0 mmHg vs. 8.2 mmHg, p < 0.001), there was a trend to less paravalvular regurgitation (PVR moderate or severe: 1% vs. 3.6%, p = 0.088). All-cause mortality up to 5 years did not show a difference (mean survival S3 3.5 ± 0.24 years, ER 3.3 ± 0.29 years, p = 0.895). Independent predictors of long-term mortality were impaired LVEF, chronic kidney injury, peripheral artery disease, malignant tumor and periprocedural stroke. New generation TAVR valves offer an excellent implant and outcome success rate. Long-term survival was independent of prostheses choice and mainly attributed to comorbidities and complications. MDPI 2021-07-14 /pmc/articles/PMC8303957/ /pubmed/34300268 http://dx.doi.org/10.3390/jcm10143102 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tamm, Alexander R. Geyer, Martin Kreidel, Felix Dausmann, Lea Jablonski, Caroline Hahad, Omar Schulz, Eberhard Münzel, Thomas Von Bardeleben, Ralph Stephan Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement |
title | Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement |
title_full | Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement |
title_fullStr | Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement |
title_full_unstemmed | Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement |
title_short | Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement |
title_sort | long-term outcome with new generation prostheses in patients undergoing transcatheter aortic valve replacement |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303957/ https://www.ncbi.nlm.nih.gov/pubmed/34300268 http://dx.doi.org/10.3390/jcm10143102 |
work_keys_str_mv | AT tammalexanderr longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement AT geyermartin longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement AT kreidelfelix longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement AT dausmannlea longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement AT jablonskicaroline longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement AT hahadomar longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement AT schulzeberhard longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement AT munzelthomas longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement AT vonbardelebenralphstephan longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement |